Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad W, Mueller RP, Kurtz J, Morgan DA, Dubois JB, Salamon E, Mirimanoff R, Bolla M, Van der Hulst M, Wárlám-Rodenhuis CC, Bartelink H, EORTC Radiation Oncology Group., et al.
European journal of cancer (Oxford, England : 1990). Date of publication 2008 Nov 1;volume 44(17):2587-99.
1. Eur J Cancer. 2008 Nov;44(17):2587-99. doi: 10.1016/j.ejca.2008.07.032. Epub 2008
Aug 29.
Predictors of the risk of fibrosis at 10 years after breast conserving therapy
for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost
versus no boost'.
Collette S(1), Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H,
Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad W, Mueller RP, Kurtz J,
Morgan DA, Dubois JB, Salamon E, Mirimanoff R, Bolla M, Van der Hulst M,
Wárlám-Rodenhuis CC, Bartelink H; EORTC Radiation Oncology Group.
Collaborators: Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den
Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Müller RP, Kurtz J, Morgan DA,
Dubois JB, Salamon E, Mirimanoff RO, Leer JW, Bolla M, Kuten A, Renaud A, Schulz
U, Koper PC, Van den Weyngaert D, Storme GA, Calitchi GH, Budach W, Roth S,
Poulsen M, Dominguez MA, Monpetit E, Kovner F, Biete Sola A, Calvo F, Vrieling C,
Barillot I, Borger J.
Author information:
(1)Statistics Department, EORTC Headquarters, Brussels, Belgium.
sandra.collette@eortc.be
Erratum in
Eur J Cancer. 2009 Jul;45(11):2061.
The EORTC 22881-10882 trial in 5178 conservatively treated early breast cancer
patients showed that a 16 Gy boost dose significantly improved local control, but
increased the risk of breast fibrosis. To investigate predictors for the
long-term risk of fibrosis, Cox regression models of the time to moderate or
severe fibrosis were developed on a random set of 1797 patients with and 1827
patients without a boost, and validated in the remaining set. The median
follow-up was 10.7 years. The risk of fibrosis significantly increased (P<0.01)
with increasing maximum whole breast irradiation (WBI) dose and with concomitant
chemotherapy, but was independent of age. In the boost arm, the risk further
increased (P<0.01) if patients had post-operative breast oedema or haematoma, but
it decreased (P<0.01) if WBI was given with >6 MV photons. The c-index was around
0.62. Nomograms with these factors are proposed to forecast the long-term risk of
moderate or severe fibrosis.
DOI: 10.1016/j.ejca.2008.07.032
PMID: 18757193 [Indexed for MEDLINE]
